En
Non vérifié

EnteroBiotix

Ce que nous écrivons

Annonces ÉconomiquesBiotechnologiePublicité/Marketing/Médias/Communication
13/05/2025
Biotechnologie
Publicité/Marketing/Médias/Communication
Annonces Économiques
EnteroBiotix Presents Positive Data in Liver Cirrhosis at EASL 2025
1.00
06/05/2025
Biotechnologie
Annonces Économiques
Publicité/Marketing/Médias/Communication
EnteroBiotix Presents Positive IBS-C Data at Digestive Disease Week® 2025
1.00
02/05/2025
Biotechnologie
Annonces Économiques
EnteroBiotix to Present Results from Phase 1b trial in Liver Cirrhosis at EASL Congress 2025
1.00
28/04/2025
Biotechnologie
Publicité/Marketing/Médias/Communication
Annonces Économiques
EnteroBiotix Announces Oral Presentation of Phase 2a IBS-C Results at Digestive Disease Week® 2025
1.00
18/03/2025
Biotechnologie
Publicité/Marketing/Médias/Communication
Annonces Économiques
EnteroBiotix Announces Positive Topline Phase 2a Results with EBX-102-02, a Potential First-in-Class Treatment for Irritable Bowel Syndrome (IBS)
1.00
18/11/2024
Biotechnologie
Publicité/Marketing/Médias/Communication
Annonces Économiques
EnteroBiotix Completes Phase 2 Study Recruitment of EBX-102-02 in Irritable Bowel Syndrome
1.00
11/11/2024
Biotechnologie
Publicité/Marketing/Médias/Communication
Annonces Économiques
EnteroBiotix Announces Positive Ph1b Clinical Results of EBX-102 in Liver Cirrhosis
1.00

Détails du contact

Réseaux sociaux

Followers
0
Compatibilité
0